Rat Model Market Size By Rat Type (Inbred, Outbred, Knockout, Hybrid), By Technology (CRISPR, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer), By Application (Research & Development, {Infectious Disease, Immunological Disease, Cancer, Car

Rat Model Market Size By Rat Type (Inbred, Outbred, Knockout, Hybrid), By Technology (CRISPR, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer), By Application (Research & Development, {Infectious Disease, Immunological Disease, Cancer, Cardiovascular Diseases, Diabetes, Genetic Diseases, Neurological Diseases}, Production and Quality Control, Academics), By Use (Human, Veterinary), By End-use (Companies {Pharmaceutical, Biotechnology, Cosmetics}, Organizations {Government, Non-Government}, Academic And Research Institutes, Contract Research Organizations), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2022 - 2028

The global rat model market is slated to expand at a substantial rate through 2028 owing to increasing number of clinical trials in the sector. In addition, surging adoption of customized medicines is set to further impel industry expansion over the forecast timeline.

Recently, industry players have been investing heavily in research & development activities, which has been favorable for market growth. To cite an instance, in November 2021, Inotiv, Inc., a global contract research organization (CRO) specializing in analytical and nonclinical drug discovery and development services, completed the acquisition of Envigo RMS Holding Corp., a leading supplier of research models as well as services. The combined company aimed to develop novel drugs and medical devices.

The rat model market has been bifurcated on the basis of rat type, technology, application, use, end use, and region. Based on rat type, the industry has been segmented into hybrid, inbred, knockout, outbred, and others. In 2021, the hybrid sub-segment was worth over USD 220 million and is anticipated to grow at a CAGR of around 6.4% through the forecast period because of their similarities to humans with regards to physiology, anatomy, and genetics.

With respect to technology, the rat model market has been categorized into nuclear transfer, CRISPR, embryonic stem cell injection, microinjection, and others. The embryonic stem cell injection sub-segment registered a valuation of around USD 220 million in 2021 and is slated to register more than 7.7% CAGR over the review timeline due to their benefits, including timesaving, cost-effective, genetic material, and so on.

From the application perspective, the industry has been classified into research & development, production and quality control, academics, and others. The academics sub-segment was worth nearly USD 24 million in 2021 and is estimated to develop at a CAGR of approximately 8.6% over the study timespan driven by increased research activity in colleges and other institutions.

Based on use, the rat model market has been divided into human and veterinary. In 2021, the veterinary sub-segment was valued at roughly USD 266 million and is set to record a growth rate of over 7.3% through 2028 because of increasing prevalence of fatal animal illnesses.

With respect to end-use, the industry has been bifurcated into companies, organizations, academic and research institutions, and contract research organizations (CRO). The contract research organizations (CRO) sub-segment was valued at more than USD 103 million in 2021 and is foreseen to register a sturdy CAGR of around 7.7% between 2022 and 2028 supported by rising R&D expenditure and growing number of clinical trials in emerging nations, among other factors.

On the regional front, the Latin America rat model market exceeded a valuation of USD 8.2 million in 2021 and is projected to witness considerable growth at a rate of about 6.9% over the assessment timeframe owing to mounting healthcare expenditure as well as increase in scientific research activities.